MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer
Publisher: Cancer BiomarkersAuthors: J. Adam, T. Sourisseau, K.A. Olaussen, A. Robin, C.Q. Zhu, A. Templier, A. Civet, P. Girard, V. Lazar, P. Validire, M. S. Tsao, J.-C. Soria, B. Besse View publication Background Resectable non-small cell lung cancer (NSCLC) treatment options most often consist of surgical resection along with adjuvant chemotherapy (ACT). The benefit of ACT however […]
